ARCHIVES

Boyd Steps Down As DTP Director, Returns to Research

This article is from The Cancer Letter archive.

Vol. 16 No. 07 | February 16, 1990

Download PDF Visit The Full Archive

Related Articles

PFS Is A Benefit “In The Right Context,” Pazdur Says In Q&A On Avastin Approval.

February 29, 2008

ORI Instructs NSAB to Prepare for Investigation

April 19, 1996

NCI Advisory Group, Other Cancer Meetings

March 31, 1989

In Setback For Generics, Court Overturns FDA.

November 9, 2001

Letter: The Lesson From Dana-Farber

July 28, 1995

Costs of Rosenberg Regimen Could Hinder cooperative Group Trials

January 3, 1986